Skip to content

CervoMed Inc.: 10-Q filed 2020-05-11

What CervoMed Inc. reported in its quarterly report filed 2020-05-11 (fiscal Q1 2020): 28 published measures, 58 facts as tagged in accession 0001437749-20-010278.

This filing

Form
10-Q (quarterly report)
Filed
2020-05-11
Fiscal period
fiscal Q1 2020
Accession
0001437749-20-010278 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CervoMed Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-03-3121,057,126USD
At 2019-12-3124,110,523USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-03-313,155,501USD
At 2019-12-313,976,261USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-03-3117,901,625USD
At 2019-12-3120,134,262USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-03-3110,828,228USD
At 2019-12-3114,177,349USD
At 2019-03-315,333,714USD
At 2018-12-317,991,172USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-2,558,815USD91
2019-01-01 to 2019-03-31-2,747,809USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-3,504,314USD91
2019-01-01 to 2019-03-31-2,657,458USD90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-03-31155,193USD91

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-03-31-94,282,893USD
At 2019-12-31-91,724,078USD

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-0.07USD/shares91
2019-01-01 to 2019-03-31-0.81USD/shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2020-01-01 to 2020-03-3134,507,496USD/shares91
2019-01-01 to 2019-03-313,376,230USD/shares90

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-362,380USD91
2019-01-01 to 2019-03-31-150,352USD90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-03-31225,346USD
At 2019-12-31252,366USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-03-31191,380USD91
2019-01-01 to 2019-03-3191,204USD90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-2,955,295USD91
2019-01-01 to 2019-03-31-2,918,845USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-03-3111,716,462USD
At 2019-12-3114,649,813USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-03-311,286,820USD
At 2019-12-311,721,421USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-03-31655,298USD
At 2019-12-311,251,412USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-01-01 to 2020-03-311,534,467USD91
2019-01-01 to 2019-03-311,699,845USD90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-03-3134,604,436shares
At 2019-12-3133,480,365shares

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2020-03-3117,901,625USD
At 2019-12-3120,134,262USD
At 2019-03-3112,954,954USD
At 2018-12-3115,611,559USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-03-31223,757USD
At 2019-12-31247,043USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2020-03-31223,757USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2020-03-31252,561USD
At 2019-12-31322,301USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2020-03-311,756,894USD
At 2019-12-312,119,274USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-2,921,195USD91
2019-01-01 to 2019-03-31-2,898,161USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-03-311,393,808USD91
2019-01-01 to 2019-03-311,200,728USD90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-01-01 to 2020-03-3127,020USD91
2019-01-01 to 2019-03-3118,272USD90

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-362,380USD91
2019-01-01 to 2019-03-31-150,352USD90

Inspect the source

Entity
CervoMed Inc. / CIK 0001053691
Captured
2026-09-20T05:17:36.273Z
SEC response SHA-256
0a28d9e08b18175e4a16bd2486e9ebae9dc8a6e8a3f7e429c0f71f98175b0255

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001053691.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))